title: Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013.
abstract: Low uptake of routinely recommended adult immunizations is a public health concern. Using data from the peer-reviewed literature, government disease-surveillance programs, and the US Census, we developed a customizable model to estimate human and economic burden caused by four major adult vaccine-preventable diseases (VPD) in 2013 in the United States, and for each US state individually. To estimate the number of cases for each adult VPD for a given population, we multiplied age-specific incidence rates obtained from the literature by age-specific 2013 Census population data. We then multiplied the estimated number of cases for a given population by age-specific, estimated medical and indirect (non-medical) costs per case. Adult VPDs examined were: (1) influenza, (2) pneumococcal disease (both invasive disease and pneumonia), (3) herpes zoster (shingles), and (4) pertussis (whooping cough). Sensitivity analyses simulated the impact of various epidemiological scenarios on the total estimated economic burden. Estimated US annual cost for the four adult VPDs was $26.5 billion (B) among adults aged 50 years and older, $15.3B (58 %) of which was attributable to those 65 and older. Among adults 50 and older, influenza, pneumococcal disease, herpes zoster, and pertussis made up $16.0B (60 %), $5.1B (19 %), $5.0B (19 %), and $0.4B (2 %) of the cost, respectively. Among those 65 and older, they made up $8.3B (54 %), $3.8B (25 %), $3.0B (20 %), and 0.2B (1 %) of the cost, respectively. Most (80-85 %) pneumococcal costs stemmed from nonbacteremic pneumococcal pneumonia (NPP). Cost attributable to adult VPD in the United States is substantial. Broadening adult immunization efforts beyond influenza only may help reduce the economic burden of adult VPD, and a pneumococcal vaccination effort, primarily focused on reducing NPP, may constitute a logical starting place. Sensitivity analyses revealed that a pandemic influenza season or change in size of the US elderly population could increase these costs dramatically.
authors.affiliation: HEOR and Epidemiology, US Medical Affairs, Pfizer Inc, New York, NY, USA, john.mclaughlin@pfizer.com.
authors.forename: John M
authors.initials: JM
authors.lastname: McLaughlin
authors.forename: Justin J
authors.initials: JJ
authors.lastname: McGinnis
authors.forename: Litjen
authors.initials: L
authors.lastname: Tan
authors.forename: Annette
authors.initials: A
authors.lastname: Mercatante
authors.forename: Joseph
authors.initials: J
authors.lastname: Fortuna
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D006562:Herpes Zoster / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control; D053061:Herpes Zoster Vaccine / Q000008:administration & dosage / Q000191:economics; D006801:Humans; D015994:Incidence; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000191:economics; D007251:Influenza, Human / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control; D008875:Middle Aged; D018803:Models, Economic; D009010:Monte Carlo Method; D010567:Pertussis Vaccine / Q000008:administration & dosage / Q000191:economics; D011008:Pneumococcal Infections / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000191:economics; D011322:Primary Prevention / Q000191:economics* / Q000379:methods; D014481:United States / Q000453:epidemiology; D014612:Vaccines / Q000008:administration & dosage / Q000191:economics*; D014917:Whooping Cough / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D053061:Herpes Zoster Vaccine; D007252:Influenza Vaccines; D010567:Pertussis Vaccine; D022242:Pneumococcal Vaccines; D014612:Vaccines